Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 449-450

  Lengerke, Claudia ^a   Haap, Michael ^b   Mayer, Frank ^a   Kanz, Lothar ^c   Kinzig, Martina ^c   Schumacher, Ulrike ^b   Sörgel, Fritz ^c   Riessen, Reimer ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFTAZIDIME; CIPROFLOXACIN; ERYTHROMYCIN; LINEZOLID; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DRUG BLOOD LEVEL; ENTEROCOCCUS FAECIUM; HUMAN; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; CEREBROSPINAL FLUID; HUMANS; MALE; MENINGES; MINOCYCLINE; TANDEM MASS SPECTROMETRY;

EID: 78650650402     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00635-10     Document Type: Letter

References (11)

1. Hoban, D. J., S. K. Bouchillon, B. M. Johnson, J. L. Johnson, and M. J. Dowzicky. 2005. In vitro activity of tigecycline against 6,792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52:215-227.
2. Jaspan, H. B., A. W. Brothers, A. J. Campbell, J. K. McGuire, S. R. Browd, T. J. Manley, D. Pak, and S. J. Weissman. 2010. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr. Infect. Dis. J. 29:379-381.
3. Nau, R., F. Sörgel, and H. Eiffert. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883.
4. Pachon-Ibanez, M. E., M. E. Jimenez-Mejias, C. Pichardo, A. C. Llanos, and J. Pachon. 2004. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48:4479-4481.
5. Pankey, G. A. 2005. Tigecycline. J. Antimicrob. Chemother. 56:470-480.
6. Pankey, G. A., and D. S. Ashcraft. 2009. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by timekill assay. Diagn. Microbiol. Infect. Dis. 64:300-304.
7. Rodvold, K. A., M. H. Gotfried, M. Cwik, J. M. Korth-Bradley, G. Dukart, and E. J. Ellis-Grosse. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58:1221-1229.
8. Tutuncu, E. E., F. Kuscu, Y. Gurbuz, B. Ozturk, A. Haykir, and I. Sencan. 2010. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int. J. Infect. Dis. 14(Suppl. 3):e224-e226.
9. Van Wart, S. A., B. B. Cirincione, E. A. Ludwig, A. K. Meagher, J. M. Korth-Bradley, and J. S. Owen. 2007. Population pharmacokinetics of tigecycline in healthy volunteers. J. Clin. Pharmacol. 47:727-737.
10. Wadi, J. A., and M. A. Al Rub. 2007. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann. Saudi Med. 27:456-458.
11. Waites, K. B., L. B. Duffy, and M. J. Dowzicky. 2006. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. 50:3479-3484.